Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: An exploratory analysis from the aphrodite data

N. Cassano, A. Galluccio, C. De Simone, F. Loconsole, S. D. Massimino, A. Plumari, S. Dattola, A. Puglisi Guerra, L. Donato, F. Cantoresi, O. De Pità, G. Fenizi, V. Altamura, M. Congedo, R. Pellicano, G. A. Vena

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor (TNF)-alpha, which is effective for the treatment of psoriasis and psoriatic arthritis (PsA). The aim of this study is to determine whether the response of psoriasis to adalimumab treatment might be influenced by certain particular factors, such as body mass index (BMI), history of biologic therapy, blood hypertension and metabolic comorbidities. For this reason, an exploratory analysis was conducted on 144 patients with psoriasis and concomitant PsA treated with adalimumab 40 mg every other week, evaluating the influence of such factors on the Psoriasis Area and Severity Index (PASI) response rate at week 12. Our preliminary results suggest that the response rate at week 12, in terms of both PASI-50 and PASI-75, appeared to be independent of the presence of hypertension and/or metabolic comorbidities. The PASI-50 response was observed more frequently in patients with BMI less than 30 as compared to obese patients (79% vs 58%, p = 0.02). Previous use of anti-TNF biologics did not appear to affect per se the rate of responders, although it was associated with a lower PASI-75 rate among responders.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalJournal of Biological Regulators and Homeostatic Agents
Volume22
Issue number4
Publication statusPublished - Oct 2008

Fingerprint

Psoriasis
Comorbidity
Body Mass Index
Psoriatic Arthritis
Therapeutics
Tumor Necrosis Factor-alpha
Hypertension
Biological Therapy
Adalimumab
Biological Products
Monoclonal Antibodies

Keywords

  • Adalimumab
  • Blood hypertension
  • Body mass index
  • Metabolic comorbidities
  • Psoriasis
  • Response

ASJC Scopus subject areas

  • Oncology
  • Endocrinology, Diabetes and Metabolism
  • Physiology (medical)
  • Immunology and Allergy
  • Immunology
  • Endocrinology
  • Physiology
  • Cancer Research

Cite this

Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab : An exploratory analysis from the aphrodite data. / Cassano, N.; Galluccio, A.; De Simone, C.; Loconsole, F.; Massimino, S. D.; Plumari, A.; Dattola, S.; Guerra, A. Puglisi; Donato, L.; Cantoresi, F.; De Pità, O.; Fenizi, G.; Altamura, V.; Congedo, M.; Pellicano, R.; Vena, G. A.

In: Journal of Biological Regulators and Homeostatic Agents, Vol. 22, No. 4, 10.2008, p. 233-237.

Research output: Contribution to journalArticle

Cassano, N, Galluccio, A, De Simone, C, Loconsole, F, Massimino, SD, Plumari, A, Dattola, S, Guerra, AP, Donato, L, Cantoresi, F, De Pità, O, Fenizi, G, Altamura, V, Congedo, M, Pellicano, R & Vena, GA 2008, 'Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: An exploratory analysis from the aphrodite data', Journal of Biological Regulators and Homeostatic Agents, vol. 22, no. 4, pp. 233-237.
Cassano, N. ; Galluccio, A. ; De Simone, C. ; Loconsole, F. ; Massimino, S. D. ; Plumari, A. ; Dattola, S. ; Guerra, A. Puglisi ; Donato, L. ; Cantoresi, F. ; De Pità, O. ; Fenizi, G. ; Altamura, V. ; Congedo, M. ; Pellicano, R. ; Vena, G. A. / Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab : An exploratory analysis from the aphrodite data. In: Journal of Biological Regulators and Homeostatic Agents. 2008 ; Vol. 22, No. 4. pp. 233-237.
@article{f05e78806f5b4a65a373bc55ad356052,
title = "Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: An exploratory analysis from the aphrodite data",
abstract = "Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor (TNF)-alpha, which is effective for the treatment of psoriasis and psoriatic arthritis (PsA). The aim of this study is to determine whether the response of psoriasis to adalimumab treatment might be influenced by certain particular factors, such as body mass index (BMI), history of biologic therapy, blood hypertension and metabolic comorbidities. For this reason, an exploratory analysis was conducted on 144 patients with psoriasis and concomitant PsA treated with adalimumab 40 mg every other week, evaluating the influence of such factors on the Psoriasis Area and Severity Index (PASI) response rate at week 12. Our preliminary results suggest that the response rate at week 12, in terms of both PASI-50 and PASI-75, appeared to be independent of the presence of hypertension and/or metabolic comorbidities. The PASI-50 response was observed more frequently in patients with BMI less than 30 as compared to obese patients (79{\%} vs 58{\%}, p = 0.02). Previous use of anti-TNF biologics did not appear to affect per se the rate of responders, although it was associated with a lower PASI-75 rate among responders.",
keywords = "Adalimumab, Blood hypertension, Body mass index, Metabolic comorbidities, Psoriasis, Response",
author = "N. Cassano and A. Galluccio and {De Simone}, C. and F. Loconsole and Massimino, {S. D.} and A. Plumari and S. Dattola and Guerra, {A. Puglisi} and L. Donato and F. Cantoresi and {De Pit{\`a}}, O. and G. Fenizi and V. Altamura and M. Congedo and R. Pellicano and Vena, {G. A.}",
year = "2008",
month = "10",
language = "English",
volume = "22",
pages = "233--237",
journal = "Journal of Biological Regulators and Homeostatic Agents",
issn = "0393-974X",
publisher = "Biolife s.a.s.",
number = "4",

}

TY - JOUR

T1 - Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab

T2 - An exploratory analysis from the aphrodite data

AU - Cassano, N.

AU - Galluccio, A.

AU - De Simone, C.

AU - Loconsole, F.

AU - Massimino, S. D.

AU - Plumari, A.

AU - Dattola, S.

AU - Guerra, A. Puglisi

AU - Donato, L.

AU - Cantoresi, F.

AU - De Pità, O.

AU - Fenizi, G.

AU - Altamura, V.

AU - Congedo, M.

AU - Pellicano, R.

AU - Vena, G. A.

PY - 2008/10

Y1 - 2008/10

N2 - Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor (TNF)-alpha, which is effective for the treatment of psoriasis and psoriatic arthritis (PsA). The aim of this study is to determine whether the response of psoriasis to adalimumab treatment might be influenced by certain particular factors, such as body mass index (BMI), history of biologic therapy, blood hypertension and metabolic comorbidities. For this reason, an exploratory analysis was conducted on 144 patients with psoriasis and concomitant PsA treated with adalimumab 40 mg every other week, evaluating the influence of such factors on the Psoriasis Area and Severity Index (PASI) response rate at week 12. Our preliminary results suggest that the response rate at week 12, in terms of both PASI-50 and PASI-75, appeared to be independent of the presence of hypertension and/or metabolic comorbidities. The PASI-50 response was observed more frequently in patients with BMI less than 30 as compared to obese patients (79% vs 58%, p = 0.02). Previous use of anti-TNF biologics did not appear to affect per se the rate of responders, although it was associated with a lower PASI-75 rate among responders.

AB - Adalimumab is a fully human monoclonal antibody directed against tumor necrosis factor (TNF)-alpha, which is effective for the treatment of psoriasis and psoriatic arthritis (PsA). The aim of this study is to determine whether the response of psoriasis to adalimumab treatment might be influenced by certain particular factors, such as body mass index (BMI), history of biologic therapy, blood hypertension and metabolic comorbidities. For this reason, an exploratory analysis was conducted on 144 patients with psoriasis and concomitant PsA treated with adalimumab 40 mg every other week, evaluating the influence of such factors on the Psoriasis Area and Severity Index (PASI) response rate at week 12. Our preliminary results suggest that the response rate at week 12, in terms of both PASI-50 and PASI-75, appeared to be independent of the presence of hypertension and/or metabolic comorbidities. The PASI-50 response was observed more frequently in patients with BMI less than 30 as compared to obese patients (79% vs 58%, p = 0.02). Previous use of anti-TNF biologics did not appear to affect per se the rate of responders, although it was associated with a lower PASI-75 rate among responders.

KW - Adalimumab

KW - Blood hypertension

KW - Body mass index

KW - Metabolic comorbidities

KW - Psoriasis

KW - Response

UR - http://www.scopus.com/inward/record.url?scp=58149350282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149350282&partnerID=8YFLogxK

M3 - Article

C2 - 19036225

AN - SCOPUS:58149350282

VL - 22

SP - 233

EP - 237

JO - Journal of Biological Regulators and Homeostatic Agents

JF - Journal of Biological Regulators and Homeostatic Agents

SN - 0393-974X

IS - 4

ER -